Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study.
Florencia S PieriniEliana BottaEnrique Roberto SorianoMaximiliano MartinLaura BoeroTomás MeroñoMaría Soledad SaezEzequiel Lozano ChiappeOsvaldo CerdaGustavo CiteraIgnacio GandinoJavier RosaPatricia SorrocheAnatol KontushFernando BritesPublished in: Rheumatology and therapy (2021)
Treatment with tocilizumab reduced hsCRP levels and displayed positive effects on certain lipoprotein-related parameters, such as a potent decrease inLp(a) and a reduction in OxLDL levels. Moreover, HDL capacity to promote cellular cholesterol efflux was maintained after 3 months of treatment.